Ambiance Ventures™ and bioaccess™ Enter into Cooperation Agreement for their Commercialization Services in Latin America
“We have found a great match in our search for a strategic partner in Latin America. On top of in-depth knowledge of their local markets and regulations, both bioaccess™ and AV share a commitment to reliability, cost-efficiency, speed, and client success. Our synergistic partnership affords significant advantages for those looking to achieve commercial success in the region. I am privileged to have bioaccess™ as our partner in Latin America.”
[ORLANDO, FL, June 3, 2021] - Ambiance Ventures™ ("AV"), a Division of Nadkarni Media Group LLC, a Pennsylvania based advisory company specialized in managing corporate innovation and business development programs for life science companies; and bioaccess™- a Colombia and Florida based clinical research and regulatory services company, are pleased to announce a cooperation agreement for licensing innovative medical products, clinical trials regulatory processing, and marketing/distribution in Latin America.
Over the last 20+ years, AV has developed a hand-holding process to work with start-ups and accelerator phase companies, assisting them in taking their intellectual property (IP) to market. Jay Nadkarni, the CEO and principal advisor at AV, brings 20+ years of experience in new product commercialization and IP licensing for biopharmaceuticals, biologics, and over-the-counter (OTC) drugs. Jay has to his credit many successful licensing deals brought to fruition with a commendable track record in innovation management, IP licensing, and technology transfers. He has international experience with a focus on tier 1 and 2 emerging markets. Jay has demonstrated leadership in research & development (R&D) strategy, execution, and key opinion leader development. With a focus on vaccines, immunotherapy, oncology, and infectious diseases, he is an industry-recognized expert with unique abilities to validate and bridge market needs with pragmatic solutions and offer actionable proposals for measuring returns on investment.
There are currently thousands of registered and active clinical trials in Latin America. Brazil, Mexico, Colombia, and Argentina receive the greatest number of clinical trials in the region. Yet, Latin America is one of the hitherto unexplored regions for clinical trials, and it's right in the US' backyard. Clinical research sites in Latin America are well developed and competent. The US FDA accepts clinical data from overseas sites in Latin America as long as sites follow international Good Clinical Practice (GCP) guidelines. Clinical trial sponsors often consider Latin American sites during early phases of drug development because of numerous advantages, including faster patient recruitment and lower cost. The concentration of potential trial subjects within a diverse population of 650+ million facilitates rapid patient recruitment in Latin America. While the Southern Hemisphere affords year-round recruitment for seasonal diseases, the region enjoys a heterogeneous ethnic and epidemiological profile, resulting in solid enrollment rates and higher patient compliance. There is also a substantial market for subsequent sale of approved drugs.
Since 2010, bioaccess™, led by Julio Martinez-Clark, is a force to reckon with in all Latin American markets and has consistently provided clinical trial services and regulatory compliance consulting to US and EU companies. bioaccess™ specializes in providing companies cost-effective regulatory approval at Colombia's INVIMA for investigational (early-stage clinical trials) as well as commercial products. bioaccess™also assists its clients with marketing plans and distributor search in Colombia, Brazil, Mexico, Argentina, and 25 other Central and South American countries.
"We have found a great match in our search for a strategic partner in Latin America. On top of in-depth knowledge of their local markets and regulations, both bioaccess™ and AV share a commitment to reliability, cost-efficiency, speed, and client success. Our synergistic partnership affords significant advantages for those looking to achieve commercial success in the region. I am privileged to have bioaccess™ as our partner in Latin America," said Jay Nadkarni.
###
About Ambiance Ventures™
Ambiance Ventures™ has a proven track record of success in new product commercialization, managing innovation programs, market launch, payer support, technology transfers, and capital sourcing. The company brings expertise in global marketing for pharmaceutical, biotechnology, and medical devices in the US, Europe, Latin America, S. Korea, and India. Learn more about how we can help you grow at Ambiance-Ventures.com.
About bioaccess™
bioaccess™ (www.bioaccessla.com) is a Colombia and US-based Contract Research Organization, regulatory and market access consulting company that delivers a full spectrum of offerings from bench to commercialization so that global pharmaceutical and medical device companies can have long-term success in Colombia, Brazil, Mexico, Argentina, and the rest of Latin America.
Media Contact:
Ambiance Ventures™
(Division of Nadkarni Media Group, LLC)
Jay Nadkarni,
Chief Executive Officer & Principal Advisor
jay@ambiance-ventures.com
bioaccess™
Julio G. Martinez-Clark,
Chief Executive Officer
jmclark@bioaccessla.com